| Price | 117.20p on 19-03-2026 at 18:40:08 |
|---|---|
| Change | -1.20p -1.01% |
| Buy | 118.40p |
| Sell | 117.60p |
| Last Trade: | Unknown 50,000.00 at 117.20p |
| Day's Volume: | 357,049 |
| Last Close: | 117.20p |
| Open: | 118.00p |
| ISIN: | GB00BY2Z0H74 |
| Day's Range | 115.00p - 118.40p |
| 52wk Range: | 100.40p - 148.00p |
| Market Capitalisation: | £283.40m |
| VWAP: | 117.09022p |
| Shares in Issue: | 241.81m |
PureTech (PRTC) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 50,000 | 117.20p | OTC Trade |
17:05:53 - 19-Mar-26 |
| Sell* | 1,614 | 117.20p | Automatic Execution |
16:35:16 - 19-Mar-26 |
| Sell* | 59,943 | 117.20p | Uncrossing Trade |
16:35:16 - 19-Mar-26 |
| Buy* | 424 | 118.00p | Automatic Execution |
16:28:00 - 19-Mar-26 |
| Buy* | 46 | 118.00p | Automatic Execution |
16:28:00 - 19-Mar-26 |
| Buy* | 58 | 118.00p | Automatic Execution |
16:26:50 - 19-Mar-26 |
| Buy* | 510 | 118.00p | Automatic Execution |
16:26:50 - 19-Mar-26 |
| Buy* | 127 | 118.00p | Automatic Execution |
16:25:09 - 19-Mar-26 |
| Buy* | 317 | 118.00p | Automatic Execution |
16:25:09 - 19-Mar-26 |
| Buy* | 443 | 118.00p | Automatic Execution |
16:24:41 - 19-Mar-26 |
PureTech (PRTC) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 13th Mar 2026 4:35 pm | RNS | PDMR Notification RSU Vesting |
| 2nd Mar 2026 7:00 am | RNS | Total Voting Rights |
| 25th Feb 2026 7:00 am | RNS-R | PRTC to Present at Leerink Healthcare Conference |
| 19th Feb 2026 5:15 pm | RNS-R | PRTC's Deupirfenidone Granted FDA & EU ODD for IPF |
| 6th Jan 2026 12:00 pm | RNS-R | PureTech to Present at the JP Morgan Conference |
| 18th Dec 2025 7:00 am | RNS | PureTech Appoints Robert Lyne as CEO |
| 10th Dec 2025 5:41 pm | RNS | Results of AGM on June 16, 2025 – Update Statement |
| 10th Dec 2025 5:30 pm | RNS | Holding(s) in Company |
| 8th Dec 2025 7:00 am | RNS-R | PRTC: Successful FDA Meeting; IPF Phase 3 in 1H26 |
| 5th Dec 2025 6:00 pm | RNS-R | PRTC's Gallop: Positive Initial Topline AML Data |
